CIN: L15142RJ1991PLC006353

## SARDA PROTEINS LTD.

Date: 29th October, 2021

To, BSE Limited, Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001

(BY BSE LISTING CENTRE)

Sub: Disclosure pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir /Ma'am,

In accordance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Un-audited Financial Results of the Company for the quarter and half year ended on 30<sup>th</sup> September, 2021 along with Statement of Assets and Liabilities as on that date and Cash Flow Statement for the half year ended on 30<sup>th</sup> September, 2021 and Limited Review Report thereon.

You are requested to kindly take the same on record.

Yours Faithfully,

FOR SARDA PROTEINS LTD

For SARDA PROTEINS LTD.

Sompany Secretary
AMIT KUMAR MODI

COMPANY SECRETARY & COMPLIANCE OFFICER

M. NO.: A29371

Encl: a/a


#### SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

## STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2021

		Quarter ended			Half Year ended		Rs.in Lakh	
S. No		30.09.2021 30.06.2021		30.09.2020	30.09.2021	30.09.2020	Year ended	
		Un-Audited	Un-Audited	Un-Audited	Un-Audited		31.03.2021	
I.	Revenue from Operations	74.58	69.76	1,038,14	144.34	Un-Audited 1,038,14	Audited	
11.	Other Income	2.54	2.10	2.06	4,64	4.07	1,135.9	
111.	Total Income (I+II)	77.12	71.86	1,040,20	148.98		8.3	
IV.	Expenses:			2,00,0020	140,20	1,042.21	1,144.3	
	Cost of Material Consumed			2	_			
	Purchase of Stock -in- Trade	73.58	69.75	1,000.30	143.33	1.000.00		
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)			1,000.30	140,00	1,000.30	1,098.00	
	Employee Benefit Expenses	2.87	3.68	2.62	6,55			
	Finance Cost	0.02	3.00	0.01	0.02	5.46	12.10	
	Depreciation and Amoritsation Expenses	0.02	0.02	0.08	0.02	0.01	0.14	
	Other expenses	3.02		20.11	3.02	0.16	0.05	
	Total Expenses (IV)	79.51	73.45	1,023.12		23,30	27.84	
٧.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	(2.39)			152.96	1,029.23	1,138.25	
VI.	Exceptional Items	(2.39)	(1.59)	17.08	(3.98)	12.98	6.13	
VII.	Profit/(Loss) before Tax (V-VI)	(2.39)	(1.50)	12.00			•	
	Tax Expense:	(2,39)	(1.59)	17.08	(3.98)	12.98	6.13	
	(1) Current Tax							
	(2) Deferred Tax						0,95	
	Profit/(Loss) for the period from Continuing						7,20	
IX.	Operations (VII-VIII)	(2.39)	(1.59)	17.08				
X.	Profit/(Loss) from Discontinued Operations	- (200)	- (1.57)	17.08	(3.98)	12.98	(2.02)	
XI.	Tax Expenses of Discontinued Operations	1			•	•	•	
	Profit/(Loss) from Discontinued Operations (after						*	
XII.	tax) (X-XI)							
XIII.	Profit/(Loss) for the Period (IX+XII)	(2,39)	(1.59)	17.08	(2.00)		-	
XIV.	Other Comprehensive Income		(1.52)	17.00	(3.98)	12.98	(2.02)	
	A (i) Items will not be reclassified to Profit or Loss							
	(ii) Income Tax relating to items that will not be					<del></del> -	· · · ·	
	reclassified to Profit or Loss							
	B (i) Items will be reclassified to Profit or Loss	+			_			
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	- 1	.					
cv.	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other Comprehensive Income for the period)	(2.39)	(1.59)	17.08	(3.98)	12.98	<b>13 BA</b>	
(VI.   I	Paid Up Equity Share Capital, Equity Shares Of Face Value Rs 10 each	172.59	172.59	172,59	172,59	172,59	(2.02)	
	earnings per Equity Share				4/4407	172.39	172,59	
	1) Basic	(0.14)	(0.09)	0.99	(0.23)	0.75	(0.10)	
(	2) Diluted	(0.14)	(0.09)	0.99	(0.23)	0.75	(0.12)	






### SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

## STATEMENT OF ASSETS AND LIABLITIES AS AT 30TH SEPTEMBER 2021

iii) Loans   -	0.43 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
A. ASSETS	0.43 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1.       Non-Current Assets         a) Property, Plant and Equipment       0.50         b) Capital work in progress       -         c) Investment Property       -         d) Goodwill       -         e) Other Intangible Assets       -         f) Intangible Assets under Development       -         g) Biological Assets other than bearer plants       -         h) Financial Assets       -         i) Investments       0.13         ii) Trade Receivables       -         ii) Deferred Tax Assets (net)       -         j) Other non-current Assets       -         current Assets       -         a) Inventories       -         b) Financial Assets       -         i) Investments       -         ii) Trade Receivables       -         iii) Cash and Cash Equivalents       0.03         iv) Bank Balances and other than (iii) above       2.03         v) Loans       97.36       9	0.43
a) Property, Plant and Equipment b) Capital work in progress c) Investment Property d) Goodwill c) Other Intangible Assets e) Other Intangible Assets f) Intangible Assets under Development g) Biological Assets under Development h) Financial Assets i) Investments ii) Trade Receivables iii) Loans ii) Deferred Tax Assets (net) j) Other non-current Assets Current Assets a) Inventories b) Financial Assets ii) Investments iii) Trade Receivables iii) Investments iii) Other non-current Assets current Assets a) Inventories b) Financial Assets iii) Cash and Cash Equivalents iii) Trade Receivables iii) Cash and Cash Equivalents iv) Bank Balances and other than (iii) above v) Loans v) Loans q) Others	0.13 (0 - 0.01 29.82 22
b) Capital work in progress c) Investment Property d) Goodwill e) Other Intangible Assets e) Other Intangible Assets f) Intangible Assets under Development g) Biological Assets other than bearer plants h) Financial Assets i) Investments ii) Trade Receivables iii) Loans i) Deferred Tax Assets (net) j) Other non-current Assets Current Assets a) Inventories b) Financial Assets ii) Investments iii) Trade Receivables current Assets a) Inventories b) Financial Assets ii) Investments ii) Trade Receivables iii) Cash and Cash Equivalents iii) Cash and Cash Equivalents iv) Bank Balances and other than (iii) above y) Loans y) Loans 97.36 99	0.13 (0 - 0.01 29.82 22
C) Investment Property	0.13 (0 - 0.01 29.82 22
d) Goodwill	0.13 (0.01 29.82 22
e) Other Intangible Assets f) Intangible Assets under Development g) Biological Assets other than bearer plants h) Financial Assets i) Investments ii) Investments iii) Loans iii) Deferred Tax Assets (net) j) Other non-current Assets Current Assets a) Inventories b) Financial Assets ii) Investments ii) Investments	0.13 (0.01 29.82 22
f) Intangible Assets under Development  g) Biological Assets other than bearer plants  h) Financial Assets  i) Investments  ii) Investments  iii) Loans  i) Deferred Tax Assets (net)  j) Other non-current Assets  Current Assets  a) Inventories  b) Financial Assets  ii) Investments  ii) Investments	0.13 (0 - 0.01 29.82 22
g) Biological Assets other than bearer plants h) Financial Assets i) Investments 0.13 ii) Trade Receivables iii) Loans i) Deferred Tax Assets (net) j) Other non-current Assets Current Assets a) Inventories b) Financial Assets ii) Investments ii) Investments iii) Trade Receivables iii) Cash and Cash Equivalents iv) Bank Balances and other than (iii) above v) Loans v) Loans v) Others	0.13 (0 - 0.01 29.82 22
h) Financial Assets i) Investments 0.13 ii) Trade Receivables iii) Loans i) Deferred Tax Assets (net) j) Other non-current Assets Current Assets a) Inventories b) Financial Assets i) Investments ii) Trade Receivables iii) Cash and Cash Equivalents iv) Bank Balances and other than (iii) above v) Loans v) Others	0.13 (c - 0.01 29.82 22
i) Investments	0.01 29.82 22
ii) Trade Receivables	0.01 29.82 22
iii) Loans       -         i) Deferred Tax Assets (net)       -         j) Other non-current Assets       22.62         Current Assets       -         a) Inventories       -         b) Financial Assets       -         i) Investments       -         ii) Trade Receivables       82.87       9         iii) Cash and Cash Equivalents       0.03         iv) Bank Balances and other than (iii) above       2.03         v) Loans       97.36       9         v) Others       97.36       9	0.01 29.82 22
i) Deferred Tax Assets (net)  j) Other non-current Assets  Current Assets  a) Inventories  b) Financial Assets  i) Investments  ii) Trade Receivables  iii) Cash and Cash Equivalents  iv) Bank Balances and other than (iii) above  v) Loans  v) Others  22.62  2  2  2  2  2  2  2  2  2  2  2  2	0.01 29.82 22
j) Other non-current Assets  Current Assets  a) Inventories  b) Financial Assets  i) Investments  ii) Trade Receivables  iii) Cash and Cash Equivalents  iv) Bank Balances and other than (iii) above  v) Loans  v) Others  22.62  2  2  2  2  2  2  2  2  2  2  2  2	29.82 22
Current Assets	decision of the same of the sa
a) Inventories  b) Financial Assets  i) Investments  ii) Trade Receivables  iii) Cash and Cash Equivalents  iv) Bank Balances and other than (iii) above  v) Loans  v) Others  a) Inventories	0.21
b) Financial Assets i) Investments ii) Trade Receivables iii) Cash and Cash Equivalents iv) Bank Balances and other than (iii) above v) Loans v) Others	
i) Investments	-
ii) Trade Receivables	
iii) Cash and Cash Equivalents   82.87   9     iv) Bank Balances and other than (iii) above   2.03     v) Loans   97.36   9	-
iv) Bank Balances and other than (iii) above 2.03  v) Loans 97.36 9	77.11
v) Loans 2.03 v) Others 97.36 9	0.03 13
y) Others 97.36 9	4.66
., -,	5.24 99
c) Current Tax Assets (net)	- '
d) Other Current Assets	-
Total Assets -	-
A07	7.64 213.
	213.
B. EQUITY AND LIABILITIES Equity	
a) Equity Share Capital b) Other Equity 250.45 250	0.45 250
5) Office Explicit	
1-informed	7.54) (42.
Non current Liabilities	
a) Financial Liablities	
i) Borrowings	
II) Trade Payables	
A) Total Outstanding dues to MSEs	
1 B) Total Outstanding dues to Creditors other than MSE <sub>0</sub>	
in) Other Financial Liabilities	
0) Flovisions	701
Sy Deterred Tax Chapitales (net)	.01 2.0
- A Content Claudities	
Current Liabilities	
a) Financial Liablities	
i) Borrowings	
n) trade rayables	-
A) Total Outstanding dues to MSEs	
2) A bin Consumum guiles to Creditors other than MSFe	
iii) Other Financial Liabilities 0.08 0.	.03
o) Other Current Catolines	-
1 -77.1011310113	.66 3.3
1 -7 Content tax Diabities (IICt)	311
Total Equity and Liabilites   1.72   (0.   205.54   227.	





#### SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajastham)
Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com CIN: L15142RJ1991PLC006353

#### CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2021

	Particulars		Six Months ended	
			30.09,2020	Year ended 31.03,2021
		Un-Audited	Un-Audited	Audited
CAS	SH FLOW FROM OPERATING ACTIVITIES			710011011
Net	Profit before Tax and Extraordinary Items	(3.98)	12.98	6.13
- Internation	JUSTMENT FOR	V=11.5/	12.70	0.13
	reciation	0.04	0.16	0.05
	rest Received	(4.64)	(4.02)	(8.39
	it on Sale of Investment	- Vii.e.i/	(4,02)	(0.35
\$11,000,000 BROWN	dend		-	
	fit)/Loss on sale of Fixed Assets		-	•
Inter	rest Paid		0.01	0.13
	Operating Profit/(Loss) before Working Capital Charges	(8,58)	9.13	(2.08
ADJ	USTMENT FOR:	Constant	2,13	(2.00
Trad	le and other Receivables	(3.61)	(13.66)	(2.40
Inve	ntories	(5.01)	(15,00)	(2.48
Trad	le & other Payables	(1.78)	(0.48)	0.19
Othe	or Non Current Assets	(2.00)	(0.46)	
Casl	h Generated from Operations	(15.97)	(5.01)	0.22
Dire	ct Taxes Paid	(13,77)	(3.01)	(4.15
	Net Cash from Operating Activities	(15.97)	(5.01)	0.95
CAS	SH FLOW FROM INVESTING ACTIVITIES	(13.77)	(3,01)	(5.10
Capi	tal Expenditure			· · · · · · · · · · · · · · · · · · ·
Sale	of Fixed Assets			7
Profi	t/ (Loss) on sale of Fixed Assets	-	•	-
Profi	t on sale of Investment		•	*
	of Investment			*
Intere	cst Received	4,64	100	
Divid	lend Received		4.02	8.39
	Net Cash Received from Investing Activities	4.64		
CAS	H FLOW FROM FINANCING ACTIVITIES	4,04	4.02	8.39
	eeds from Long Term Borrowings		(4.75)	
	eeds from Short Term Borrowings		(4.55)	-
	est Paid	-	7	
	Net Cash Inflow/ (Outflow) from Financing Activities	*	(0.01)	(0.13)
	Act Cash fation (Outhor) from Financing Activities	-	(4.56)	(0.13)
Net (	Cash Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)			
Cach	& Cash Equivalents (Opening)	(11.33)	(5.55)	3.16
	& Cash Equivalants (Closing)	13.39	10.24	10.23
Cusu	es cusu reduitatures (Ciosina)	2.06	4.69	13,39

#### Notes:

- 1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 29th October 2021.
- 2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account,

alawal Agaru

" Accoun

- 3. Segment Results as per AS is not applicable as dealing in only one segment i.e. " Agro Products".
- 4. No Investor Complaints were received during the quarter ended 30-Sep-2021 nor any pending as on 01-Oct-2021.

5. Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

on behalf of the Board

Sarda Proteins Ltd

Place: Jaipur Date: 29-Oct-2021 Deepak Data (DIN: 01672415)

Managing Director



# Khetawat Agarwal & Co.

#### **Limited Review Report** Unaudited Standalone Quarterly and Half Year Results

To The Board of Directors Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of SARDA PROTEINS LTD for the Quarter and Half Year ended on 30th September, 2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khetawat Agarwal & Co. Mal Agarwa,

**Chartered Accountants** 

FRN: 003960C

M.L. Agarwal Partner

M. No.: 072854

UDIN: 21072854AAAACT2323

Tered Acco

Place : Jaipur Date : 29.10.2021

Phone: Office 0144 - 2340924, 7014347644 Mobile : 9414215353 (ML Agarwal) E-mail: khetawatagarwal21@gmail.com